Mycobacterium tuberculosis RmlC epimerase (Rv3465): a promising drug-target structure in the rhamnose pathway

The Mycobacterium tuberculosis rmlC gene encodes dTDP‐4‐­keto‐6‐deoxyglucose epimerase, the third enzyme in the M. tuberculosis dTDP‐l‐rhamnose pathway which is essential for mycobacterial cell‐wall synthesis. Because it is structurally unique, highly substrate‐specific and does not require a cofact...

Full description

Saved in:
Bibliographic Details
Published in:Acta crystallographica. Section D, Biological crystallography. Biological crystallography., 2004-05, Vol.60 (5), p.895-902
Main Authors: Kantardjieff, Katherine A., Kim, Chang-Yub, Naranjo, Cleo, Waldo, Geoffry S., Lekin, Timothy, Segelke, Brent W., Zemla, Adam, Park, Min S., Terwilliger, Thomas C., Rupp, Bernhard
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Binding Sites
Carbohydrate Epimerases - chemistry
Carbohydrate Epimerases - metabolism
Crystallography, X-Ray
Dimerization
Drug Design
drug-target structure
dTDP-4-keto-6-deoxyglucose epimerase
Genomics
International Cooperation
Models, Molecular
Molecular Sequence Data
Mycobacterium tuberculosis
Mycobacterium tuberculosis - enzymology
Mycobacterium tuberculosis - metabolism
Pilot Projects
Protein Conformation
Rhamnose - metabolism
rhamnose pathway
RmlC
Rv3456
Sequence Homology, Amino Acid
Structural Homology, Protein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Mycobacterium tuberculosis rmlC gene encodes dTDP‐4‐­keto‐6‐deoxyglucose epimerase, the third enzyme in the M. tuberculosis dTDP‐l‐rhamnose pathway which is essential for mycobacterial cell‐wall synthesis. Because it is structurally unique, highly substrate‐specific and does not require a cofactor, RmlC is considered to be the most promising drug target in the pathway, and the M. tuberculosisrmlC gene was selected in the initial round of TB Structural Genomics Consortium targets for structure determination. The 1.7 Å native structure determined by the consortium facilities is reported and implications for in silico screening of ligands for structure‐guided drug design are discussed.
ISSN:1399-0047
0907-4449
1399-0047
DOI:10.1107/S0907444904005323